Requir Global Regulatory Lead at AstraZeneca
AstraZeneca contributes meaningfully to the UK beyond the provision of our medicines and the benefits they provide to the health of the nation.
We commissioned a report in 2009 to measure our significant investment to the UK economy, which includes investment in jobs and wealth creation. Oxera, an independent economic consultancy provided the analysis for this report.
The report looks at our contribution to the UK as a whole as well as at individual countries within the UK, and at regions where AstraZeneca has a significant presence, identifying the company’s local impact in terms of spending, jobs and economic prosperity.
Post : Global Regulatory Lead - Associate Director

The flagship company of the Piramal Group, Piramal Enterprises Ltd. (PEL), has business interests in Pharma, Information Management, and Financial Services verticals of the group. Towards the late 80s, we shifted our focus from textile to pharmaceuticals. We chose to invest significantly in the domestic formulation development business, while other companies in the industry concentrated on international generics. Our efforts proved successful with a track record of approximately 23% revenue CAGR. In 2010, our strategy accomplished a sale of its domestic formulations business at an unprecedented value of ~9x sales and ~30x EBITDA.


